VIDEO: Ocular Therapeutix shares update on phase 3 Axpaxli studies

ByPravin U. Dugel, MD

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Pravin U. Dugel, MD, of Ocular Therapeutix discusses the next steps for the phase 3 SOL-1 and SOL-R studies.

The studies, which are investigating Axpaxli (axitinib intravitreal implant) for the treatment of wet age-related macular degeneration, are moving toward completion of randomization for SOL-1 and enrollment for SOL-R.

“We’ve designed these two studies not only to be complementary but to be strategic in a way that all the questions that I believe the investigators as well as the physicians will have will be answered,” Dugel said.

Reference:

Ocular Therapeutix announces accelerated timelines for SOL-1 registrational trial of Axpaxli in wet AMD. https://investors.ocutx.com/news-releases/news-release-details/ocular-therapeutixtm-announces-accelerated-timelines-sol-1. Published Oct. 15, 2024. Accessed Oct. 21, 2024.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Dugel reports being executive chairman, president and CEO of Ocular Therapeutix.

American Academy of Ophthalmology Meeting

Read more

VIDEO: Ocular Therapeutix shares update on phase 3 Axpaxli studies

Reference:

Related Content